STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 490.20+SEK 2.20 (+0.45%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.37% below the high.
Loading market information…
STO · CEVI.ST · SEK
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 11:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
CellaVision AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
CellaVision AB (publ)’s forward annual dividend is SEK 2.75 per share, paid annual. The forward yield is 1.41% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
CellaVision AB (publ)’s next earnings report is currently expected on Feb 4, 2027, with estimated earnings per share of SEK 2.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CellaVision AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Jul 18, 2025 | SEK 1.60-3.03% vs estimate | SEK 191.30M-0.1% vs estimate |
|---|
| Q1 2025 | Apr 28, 2025 | SEK 1.70+23.19% vs estimate | SEK 194.90M+11.38% vs estimate |
|---|
| Q4 2024 | Feb 6, 2025 | SEK 1.70-11.92% vs estimate | SEK 187.00M-7.67% vs estimate |
|---|
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 490.20+SEK 2.20 (+0.45%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.37% below the high.
SEK 277.70+SEK 4.30 (+1.57%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 1.07% below the high.
SEK 346.00+SEK 4.40 (+1.29%)
Sectra AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.06% below the high.
SEK 283.50+SEK 4.00 (+1.43%)
Medicover AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.35% below the high.
SEK 673.00+SEK 3.00 (+0.45%)
Camurus AB’s quoted price sits in the upper half of its reported 52-week range, 5.21% below the high.
SEK 317.20-SEK 2.20 (-0.69%)
BioArctic AB’s quoted price sits in the upper half of its reported 52-week range, 12.95% below the high.
SEK 55.00-SEK 3.00 (-5.17%)
Devyser Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 59.14% below the high.
SEK 0.31-SEK 0.02 (-5.71%)
IDL Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 40.75% below the high.
